# A Study to Evaluate the Pharmacokinetics of Single Oral Doses of Ozanimod in Healthy Adult Chinese Subjects

> **NCT04211558** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 24 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** Ozanimod

## Key facts

- **NCT ID:** NCT04211558
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-12
- **Primary completion:** 2020-09-26
- **Final completion:** 2020-10-09
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04211558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04211558, "A Study to Evaluate the Pharmacokinetics of Single Oral Doses of Ozanimod in Healthy Adult Chinese Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04211558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*